# reload+after+2024-01-23 08:47:56.330427
address1§170 Harbor Way
address2§Suite 300
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 550 3500
fax§650 871 8580
website§https://vaxart.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
fullTimeEmployees§164
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Cezar Andrei Floroiu M.B.A.', 'age': 50, 'title': 'CEO, President & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 674977, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sean N. Tucker Ph.D.', 'age': 54, 'title': 'Senior VP & Chief Scientific Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 481522, 'exercisedValue': 0, 'unexercisedValue': 21216}, {'maxAge': 1, 'name': 'Dr. James F. Cummings M.D.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 526956, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Phillip Eric  Lee', 'age': 35, 'title': 'CFO, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1988, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Raymond D. Stapleton Jr., Ph.D.', 'age': 52, 'title': 'Chief Technology Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Edward B. Berg', 'age': 58, 'title': 'Senior VP & General Counsel', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sarah Caravalho Khan', 'title': 'VP & Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Shaily Jaini Garg', 'title': 'Senior Vice President of Clinical Development & Project Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brant  Biehn', 'title': 'Senior Vice President of Business Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rajesh  Kapoor Ph.D.', 'title': 'Senior Vice President of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§7
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
exDividendDate§1352419200
payoutRatio§0.0
beta§0.401
priceToSalesTrailing12Months§20.9767
currency§USD
dateShortInterest§1702598400
forwardEps§-0.54
exchange§NCM
quoteType§EQUITY
shortName§Vaxart, Inc. - Common Stock
longName§Vaxart, Inc.
firstTradeDateEpochUtc§376929000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4d8f7932-a203-34dc-b099-0c90a8658892
gmtOffSetMilliseconds§-18000000
targetHighPrice§8.0
targetLowPrice§1.5
targetMeanPrice§4.5
targetMedianPrice§4.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§1.798
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
